Jason Kralic

Dr. Kralic is a neuropharmacologist and business development executive with broad experience in technology innovation, CNS R&D, licensing, fundraising and company creation. Jason is Co-founder and CEO of Tellus Therapeutics focused on development of treatments for neonatal brain injury, Director of Business Development for Bioscience Pharma Partners focused on development of a treatment of neuroinflammation in neurodegenerative disorders and serves on the scientific advisory board for the Alzheimer’s disease company, T3D Therapeutics. Jason was previously Associate Vice President of Technology Innovation at Wake Forest Baptist Medical Center and Head of Business Development for Neurosciences R&D at GlaxoSmithKline during which he led the divestment of GSK’s Ph3- ready Alzheimer’s disease program, Intepirdine, to Axovant resulting in a $360M IPO (largest of 2016) and helped launch several start-up companies, including Convergence Pharmaceuticals (received $200M upfront from Biogen for license to neuropathic pain programs), PainQx (raised $5M in non-dilutive and equity funding for pain diagnostics platform) and Care Directions (>$300,000 funding for healthcare IT solution for post-stroke management). Jason has also served in business development roles at Opexa Therapeutics, UCB Pharma and Schwarz Biosciences.

Jason holds a Ph.D. in pharmacology from the University of North Carolina at Chapel Hill where he studied novel roles of ion channels in CNS drug response. His post-doctoral training at the University of Zurich focused on the biochemical, pharmacologic and behavioral responses to experimental CNS therapeutics as well as the role of neurogenesis in neurologic disorders.